Cardio Diagnostics (NASDAQ:CDIO) Releases Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) released its earnings results on Friday. The company reported ($0.80) earnings per share (EPS) for the quarter, Zacks reports. Cardio Diagnostics had a negative net margin of 39,674.18% and a negative return on equity of 67.51%.

Cardio Diagnostics Stock Performance

CDIO stock traded down $1.76 during mid-day trading on Friday, hitting $2.80. The company had a trading volume of 1,127,513 shares, compared to its average volume of 10,924,570. The firm has a market cap of $5.12 million, a PE ratio of -0.75 and a beta of 2.28. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $17.39. The stock’s fifty day moving average price is $2.68 and its two-hundred day moving average price is $3.33.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardio Diagnostics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Cardio Diagnostics

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC purchased a new position in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned 1.07% of Cardio Diagnostics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.